Friday, October 21, 2016

Pseudo GG


Generic Name: guaifenesin and pseudoephedrine (gwye FEN e sin, SOO doe ee FED rin)

Brand Names: Altarussin PE, Ambifed, Ambifed-G, Biotuss PE, Congestac, D-Feda II, Despec-SR, Dynex, Entex PSE, ExeFen, ExeFen-IR, Guiatex II SR, Levall G, Maxifed, Maxifed-G, Medent LD, Medent-LDI, Mucinex D, Mucinex D Max Strength, Nasabid SR, Nasatab LA, Nomuc-PE, Poly-Vent, Poly-Vent IR, Poly-Vent, Jr., Pseudatex, Pseudo GG, Pseudo GG TR, Pseudo Max, Q-Tussin PE, Respaire-120 SR, Respaire-30, Respaire-60 SR, Robitussin PE, Robitussin Severe Congestion, Ru-Tuss Jr., Sinutab Non Drying, Stamoist E, SudaTex-G, Tenar PSE, Touro LA, Touro LA-LD, Triaminic Softchews Chest Congestion, We Mist II LA, We Mist LA


What is Pseudo GG (guaifenesin and pseudoephedrine)?

Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.


Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of guaifenesin and pseudoephedrine is used to treat stuffy nose, sinus congestion, and cough caused by allergies or the common cold.


Guaifenesin and pseudoephedrine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Pseudo GG (guaifenesin and pseudoephedrine)?


Do not give this medication to a child younger than 4 years old. Alwayss ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Do not use a cough or cold medicine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects. Ask a doctor or pharmacist before using any other cold, cough, or allergy medicine. Guaifenesin and pseudoephedrine are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains guaifenesin or pseudoephedrine.

What should I discuss with my healthcare provider before taking Pseudo GG (guaifenesin and pseudoephedrine)?


You should not use this medication if you are allergic to guaifenesin or pseudoephedrine, or to other decongestants, diet pills, stimulants, or ADHD medications. Do not use a cough or cold medicine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Ask a doctor or pharmacist if it is safe for you to take this medicine if you have:



  • heart disease or high blood pressure;




  • diabetes; or




  • a thyroid disorder.




It is not known whether guaifenesin and pseudoephedrine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. Guaifenesin and pseudoephedrine may pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Artificially sweetened liquid cough or cold medicine may contain phenylalanine. If you have phenylketonuria (PKU), check the medication label to see if the product contains phenylalanine.


How should I take Pseudo GG (guaifenesin and pseudoephedrine)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Cough and cold medicine is usually taken only for a short time until your symptoms clear up.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Do not crush, chew, break, or open an extended-release tablet or capsule. Swallow it whole. Breaking or opening the pill may cause too much of the drug to be released at one time.

Measure liquid medicine with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Drink extra fluids to help loosen the congestion and lubricate your throat while you are taking this medication. Take with food if this medicine upsets your stomach. Do not take guaifenesin and pseudoephedrine for longer than 7 days in a row. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash.

If you need surgery, tell the surgeon ahead of time if you have taken a cough or cold medicine within the past few days.


Store at room temperature away from moisture, heat, and light.

What happens if I miss a dose?


Since cough or cold medicine is taken when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, vomiting, dizziness, and feeling restless or nervous.


What should I avoid while taking Pseudo GG (guaifenesin and pseudoephedrine)?


This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of guaifenesin and pseudoephedrine.

Avoid taking this medication if you also take diet pills, caffeine pills, or other stimulants (such as ADHD medications). Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.


Ask a doctor or pharmacist before using any other cold, cough, or allergy medicine. Guaifenesin and pseudoephedrine are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains guaifenesin or pseudoephedrine.

Pseudo GG (guaifenesin and pseudoephedrine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have a serious side effect such as:

  • fast, pounding, or uneven heartbeat;




  • severe dizziness, anxiety, or nervousness;




  • easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms; or




  • increased blood pressure (severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure).



Less serious side effects may include:



  • dizziness or headache;




  • feeling restless or excited;




  • sleep problems (insomnia);




  • mild nausea, vomiting, or stomach upset;




  • mild loss of appetite;




  • warmth, redness, or tingly feeling under your skin; or




  • skin rash or itching.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Pseudo GG (guaifenesin and pseudoephedrine)?


Tell your doctor about all other medicines you use, especially:



  • methyldopa (Aldomet);




  • blood pressure medications;




  • a beta-blocker such as atenolol (Tenormin, Tenoretic), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), and others; or




  • an antidepressant such as amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Janimine, Tofranil), and others.



This list is not complete and other drugs may interact with guaifenesin and pseudoephedrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Pseudo GG resources


  • Pseudo GG Side Effects (in more detail)
  • Pseudo GG Use in Pregnancy & Breastfeeding
  • Pseudo GG Drug Interactions
  • Pseudo GG Support Group
  • 0 Reviews for Pseudo GG - Add your own review/rating


  • Congestac MedFacts Consumer Leaflet (Wolters Kluwer)

  • Entex PSE Controlled-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • Mucinex D Prescribing Information (FDA)

  • Mucinex D Consumer Overview

  • Pseudovent Consumer Overview

  • Robitussin Severe Congestion MedFacts Consumer Leaflet (Wolters Kluwer)

  • Zephrex LA Sustained-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Pseudo GG with other medications


  • Cough and Nasal Congestion


Where can I get more information?


  • Your pharmacist can provide more information about guaifenesin and pseudoephedrine.

See also: Pseudo GG side effects (in more detail)


pyrimethamine and sulfadoxine


Generic Name: pyrimethamine and sulfadoxine (PIR i METH a meen and SUL fa DOX een)

Brand Names: Fansidar


What is pyrimethamine and sulfadoxine?

Pyrimethamine is an antiparasitic drug. It prevents the growth and reproduction of parasites.


Sulfadoxine is a sulfa drug that fights bacteria in the body.


The combination of pyrimethamine and sulfadoxine is used to treat malaria, a disease caused by parasites. Parasites that cause malaria typically enter the body through the bite of a mosquito. Malaria is common in areas such as Africa, South America, and Southern Asia.


Pyrimethamine and sulfadoxine is usually given when other anti-malaria medications may not be as effective in treatment or prevention.


Pyrimethamine and sulfadoxine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about pyrimethamine and sulfadoxine?


Do not use this medication if you have ever had a serious allergic reaction to pyrimethamine or sulfadoxine. Stop taking the medicine and call your doctor at once if you have any signs of skin rash, no matter how mild. You should not use this medication if you are allergic to sulfa drugs, or if you have liver or kidney disease (if using the medication long-term), a blood cell disorder (such as anemia), if you are in late pregnancy, or if you are breast-feeding a baby. Take the pyrimethamine and sulfadoxine tablet after a meal, with plenty of water or other fluid. Swallow the tablet whole, do not break or chew it. Drink plenty of water to keep your kidneys working and prevent kidney stones while taking this medication. You should not take pyrimethamine and sulfadoxine for longer than 2 years without a doctor's advice.

In addition to taking pyrimethamine and sulfadoxine, use protective clothing, insect repellents, and mosquito netting around your bed to further prevent mosquito bites that could cause malaria.


No medication is 100% effective in treating or preventing malaria. For best results, keep using the medication as directed. Talk with your doctor if you have fever, vomiting, or diarrhea during your treatment.


What should I discuss with my health care provider before taking pyrimethamine and sulfadoxine?


You should not use this medication if you are allergic to pyrimethamine, sulfadoxine, or other sulfa drugs, or if you have certain conditions. Be sure your doctor knows if you have:

  • liver or kidney disease (if using the medication long-term);




  • a blood cell disorder (such as anemia);




  • anemia caused by a folic acid deficiency;




  • if you are in late pregnancy; or




  • if you are breast-feeding.



Before using pyrimethamine and sulfadoxine, tell your doctor if you are allergic to any drugs, or if you have:



  • liver or kidney disease; or




  • glucose-6-phosphate dehydrogenase (G6PD) deficiency.




FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Malaria is more likely to cause death in a pregnant woman. If you are pregnant, talk with your doctor about the risks of traveling to areas where malaria is common. Do not use this medication if you are breast-feeding a baby. Do not give this medication to a child without a doctor's advice. Babies younger than 2 months old should not receive pyrimethamine and sulfadoxine.

How should I take pyrimethamine and sulfadoxine?


Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.


Take the pyrimethamine and sulfadoxine tablet after a meal, with plenty of water or other fluid. Swallow the tablet whole, do not break or chew it. Drink plenty of water to keep your kidneys working and prevent kidney stones while taking this medication.

To treat malaria, this medication is usually given as a single dose of 1/2 to 3 tablets. Follow your doctor's instructions.


If you are taking this medicine to prevent malaria, start taking it 1 or 2 days before entering an area where malaria is common. Take the medication every day during your stay and for 4 to 6 weeks after you leave.


You should not take pyrimethamine and sulfadoxine for longer than 2 years without a doctor's advice.

In addition to taking pyrimethamine and sulfadoxine, use protective clothing, insect repellents, and mosquito netting around your bed to further prevent mosquito bites that could cause malaria.


If you take this medication for longer than 3 months, your blood may need to be tested on a regular basis. Do not miss any scheduled appointments.


Contact your doctor as soon as possible if you have been exposed to malaria, or if you have fever or other symptoms of illness during or after a stay in an area where malaria is common.

No medication is 100% effective in treating or preventing malaria. For best results, keep using the medication as directed. Talk with your doctor if you have fever, vomiting, or diarrhea during your treatment.


Store pyrimethamine and sulfadoxine at room temperature away from moisture and heat.

See also: Pyrimethamine and sulfadoxine dosage (in more detail)

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include nausea, vomiting, loss of appetite, fever, chills, sore throat, swollen tongue, or seizure (convulsions).


What should I avoid while taking pyrimethamine and sulfadoxine?


Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds) while taking this medication.

Pyrimethamine and sulfadoxine side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using pyrimethamine and sulfadoxine and call your doctor at once if you have any of these serious side effects:

  • the first sign of any skin rash, no matter how mild;




  • a severe blistering, peeling, and red skin rash;




  • pale skin, easy bruising or bleeding;




  • feeling tired, weak, or dizzy;




  • hallucinations, seizure (convulsions);




  • urinating less than usual or not at all;




  • jaundice (yellowing of the skin or eyes); or




  • fever, chills, sore throat, swollen tongue, joint pain, cough, feeling short of breath.



Less serious side effects may include:



  • mild stomach pain, feeling full;




  • slight hair loss;




  • headache;




  • muscle weakness;




  • depression, nervousness;




  • ringing in your ears; or




  • sleep problems (insomnia).



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


Pyrimethamine and sulfadoxine Dosing Information


Usual Adult Dose for Malaria:

2 or 3 tablets taken orally as a single dose, following a 3 to 7 day course of quinine (650 mg every 8 hours).

Usual Adult Dose for Malaria Prophylaxis:

1 tablet orally every week beginning 1 or 2 days before departure to an endemic area; continue administration during the stay and for 4 to 6 weeks after returning.

Alternative: 2 tablets every 2 weeks beginning 1 or 2 days before departure to an endemic area; continue administration during the stay and for 4 to 6 weeks after returning.

Usual Adult Dose for Pneumocystis Pneumonia Prophylaxis:

1 tablet (25/500 mg) orally once or twice a week.

Pyrimethamine-sulfadoxine is generally not recommended for PCP prophylaxis unless trimethoprim-sulfamethoxazole, pentamidine, dapsone/pyrimethamine/leucovorin, atovaquone, or dapsone cannot be used.

Usual Pediatric Dose for Malaria:

>2 months:
5-10 kg: One-half tablet orally one time
11-20 kg: 1 tablet orally one time
21-30 kg: 1.5 tablet orally one time
31-45 kg: 2 tablets orally one time
>45 kg: 3 tablets orally one time

A 3 to 7-day course of quinine should precede the pyrimethamine-sulfadoxine dose.

Usual Pediatric Dose for Malaria Prophylaxis:

> 2 months:
5-10 kg: 1/4 (0.25) tablet orally once a week
11-20 kg: 1/2 (0.5) tablet orally once a week
21-30 kg: 3/4 (0.75) tablet orally once a week
31-45 kg: 1 tablet orally once a week
>45 kg: 1.5 tablet orally once a week

Begin 1 or 2 days before departure to an endemic area; continue administration during the stay and for 4 to 6 weeks after returning.


What other drugs will affect pyrimethamine and sulfadoxine?


Tell your doctor about any other anti-malaria medications you are taking.

The following drugs can interact with pyrimethamine and sulfadoxine. Tell your doctor if you are using any of these:



  • chloroquine (Aralen); or




  • sulfa drugs (Bactrim, Gantanol, Septra, and others);



This list is not complete and there may be other drugs that can interact with pyrimethamine and sulfadoxine. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More pyrimethamine and sulfadoxine resources


  • Pyrimethamine and sulfadoxine Side Effects (in more detail)
  • Pyrimethamine and sulfadoxine Dosage
  • Pyrimethamine and sulfadoxine Use in Pregnancy & Breastfeeding
  • Pyrimethamine and sulfadoxine Drug Interactions
  • Pyrimethamine and sulfadoxine Support Group
  • 0 Reviews for Pyrimethamine and sulfadoxine - Add your own review/rating


Compare pyrimethamine and sulfadoxine with other medications


  • Malaria
  • Malaria Prevention
  • Pneumocystis Pneumonia Prophylaxis


Where can I get more information?


  • Your pharmacist can provide more information about pyrimethamine and sulfadoxine.

See also: pyrimethamine and sulfadoxine side effects (in more detail)


Pyrinex Topical


Generic Name: pyrethrum extract and piperonyl butoxide (Topical route)


pye-REE-thrum EX-trackt, PIP-er-oh-nil byoo-TOX-ide


Commonly used brand name(s)

In the U.S.


  • A200 Maximum Strength

  • A200 Time-Tested Formula

  • Lice-X

  • Licide

  • Medi-Lice Maximum Strength

  • Pronto Maximum Strength

  • Pyrinex

  • Pyrinyl

  • Rid

  • Tisit

Available Dosage Forms:


  • Gel/Jelly

  • Liquid

  • Shampoo

  • Kit

  • Foam

Therapeutic Class: Pediculicide


Chemical Class: Pyrethrums


Uses For Pyrinex


Medicine containing pyrethrins is used to treat head, body, and pubic lice infections. This medicine is absorbed by the lice and destroys them by acting on their nervous systems. It does not affect humans in this way. The piperonyl butoxide is included to make the pyrethrins more effective in killing the lice. This combination medicine is known as a pediculicide.


This medicine is available without a prescription.


Before Using Pyrinex


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Although there is no specific information comparing use of pyrethrins and piperonyl butoxide combination in children with use in other age groups, this medicine is not expected to cause different side effects or problems in children than it does in adults.


Geriatric


Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. Although there is no specific information comparing use of pyrethrins and piperonyl butoxide combination medicine in the elderly with use in other age groups, this medicine is not expected to cause different side effects or problems in older people than it does in younger adults.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Inflammation of the skin (severe)—Use of pyrethrins and piperonyl butoxide combination may make the condition worse

Proper Use of pyrethrum extract and piperonyl butoxide

This section provides information on the proper use of a number of products that contain pyrethrum extract and piperonyl butoxide. It may not be specific to Pyrinex. Please read with care.


Pyrethrins and piperonyl butoxide combination medicine usually comes with patient directions. Read them carefully before using this medicine.


Use this medicine only as directed. Do not use more of it and do not use it more often than recommended on the label. To do so may increase the chance of absorption through the skin and the chance of side effects.


Keep pyrethrins and piperonyl butoxide combination medicine away from the mouth and do not inhale it. This medicine is harmful if swallowed or inhaled.


To lessen the chance of inhaling this medicine, apply it in a well-ventilated room (for example, one with free flowing air or with a fan turned on).


Keep this medicine away from the eyes and other mucous membranes, such as the inside of the nose, mouth, or vagina, because it may cause irritation. If you accidentally get some in your eyes, flush them thoroughly with water at once.


Do not apply this medicine to the eyelashes or eyebrows . If they become infected with lice, check with your doctor.


To use the gel or solution form of this medicine:


  • Apply enough medicine to thoroughly wet the dry hair and scalp or skin. Allow the medicine to remain on the affected areas for exactly 10 minutes.

  • Then, thoroughly wash the affected areas with warm water and soap or regular shampoo. Rinse thoroughly and dry with a clean towel.

To use the shampoo form of this medicine:


  • Apply enough medicine to thoroughly wet the dry hair and scalp or skin. Allow the medicine to remain on the affected areas for exactly 10 minutes.

  • Then use a small amount of water and work shampoo into the hair and scalp or skin until a lather forms. Rinse thoroughly and dry with a clean towel.

After rinsing and drying, use a nit removal comb (special fine-toothed comb, usually included with this medicine) to remove the dead lice and eggs (nits) from hair.


Immediately after using this medicine, wash your hands to remove any medicine that may be on them.


This medicine should be used again in 7 to 10 days after the first treatment in order to kill any newly hatched lice.


Lice can easily move from one person to another by close body contact. This can happen also by direct contact with such things as clothing, hats, scarves, bedding, towels, washcloths, hairbrushes and combs, or the hair of infected persons. Therefore, all members of your household should be examined for lice and receive treatment if they are found to be infected.


To use this medicine for pubic (crab) lice:


  • Your sexual partner may also need to be treated, since the infection may spread to persons in close contact. If your partner is not being treated or if you have any questions about this, check with your doctor.

Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For topical dosage forms (gel, solution shampoo, and topical solution):
    • For head, body, or pubic lice:
      • Adults and children—Use one time, then repeat one time in seven to ten days.



Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using Pyrinex


To prevent reinfection or spreading of the infection to other people, good health habits are also required. These include the following:


  • For head lice
    • Machine wash all clothing (including hats, scarves, and coats), bedding, towels, and washcloths in very hot water and dry them by using the hot cycle of a dryer for at least 20 minutes. Clothing or bedding that cannot be washed should be dry-cleaned or sealed in a plastic bag for 2 weeks.

    • Shampoo all wigs and hairpieces.

    • Wash all hairbrushes and combs in very hot soapy water (above 130 °F) for 5 to 10 minutes and do not share them with other people.

    • Clean the house or room by thoroughly vacuuming upholstered furniture, rugs, and floors.


  • For body lice
    • Machine wash all clothing, bedding, towels, and washcloths in very hot water and dry them by using the hot cycle of a dryer for at least 20 minutes. Clothing or bedding that cannot be washed should be dry-cleaned or sealed in a plastic bag for 2 weeks.

    • Clean the house or room by thoroughly vacuuming upholstered furniture, rugs, and floors.


  • For pubic lice
    • Machine wash all clothing (especially underwear), bedding, towels, and washcloths in very hot water and dry them by using the hot cycle of a dryer for at least 20 minutes. Clothing or bedding that cannot be washed should be dry-cleaned or sealed in a plastic bag for 2 weeks.

    • Scrub toilet seats frequently.


Pyrinex Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


Less common or rare
  • Skin irritation not present before use of this medicine

  • skin rash or infection

  • sneezing (sudden attacks of)

  • stuffy or runny nose

  • wheezing or difficulty in breathing

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Pyrinex Topical resources


  • Pyrinex Topical Use in Pregnancy & Breastfeeding
  • Pyrinex Topical Support Group
  • 0 Reviews for Pyrinex Topical - Add your own review/rating


Compare Pyrinex Topical with other medications


  • Head Lice
  • Lice

Perforomist





Dosage Form: inhalation solution
FULL PRESCRIBING INFORMATION
WARNING: ASTHMA-RELATED DEATH

Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including formoterol, the active ingredient in Perforomist Inhalation Solution. The safety and efficacy of Perforomist in patients with asthma have not been established. All LABA, including Perforomist, are contraindicated in patients with asthma without use of a long-term asthma control medication [see CONTRAINDICATION (4), WARNINGS AND PRECAUTIONS (5.1)].




Indications and Usage for Perforomist



Maintenance Treatment of COPD


Perforomist (formoterol fumarate) Inhalation Solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.



Important Limitations of Use


Perforomist Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS (5.2)].


Perforomist Inhalation Solution is not indicated to treat asthma. The safety and effectiveness of Perforomist Inhalation Solution in asthma have not been established.



Perforomist Dosage and Administration


The recommended dose of Perforomist (formoterol fumarate) Inhalation Solution is one 20 mcg unit-dose vial administered twice daily (morning and evening) by nebulization. A total daily dose greater than 40 mcg is not recommended.


Perforomist Inhalation Solution should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor. The safety and efficacy of Perforomist Inhalation Solution have been established in clinical trials when administered using the PARI-LC Plus® nebulizer (with a facemask or mouthpiece) and the PRONEB® Ultra compressor. The safety and efficacy of Perforomist Inhalation Solution delivered from non-compressor based nebulizer systems have not been established.


Perforomist Inhalation Solution should always be stored in the foil pouch, and only removed IMMEDIATELY BEFORE USE. Contents of any partially used container should be discarded.


If the recommended maintenance treatment regimen fails to provide the usual response, medical advice should be sought immediately, as this is often a sign of destabilization of COPD. Under these circumstances, the therapeutic regimen should be re-evaluated and additional therapeutic options should be considered.


The drug compatibility (physical and chemical), efficacy, and safety of Perforomist Inhalation Solution when mixed with other drugs in a nebulizer have not been established.



Dosage Forms and Strengths


Perforomist (formoterol fumarate) Inhalation Solution is supplied as a sterile solution for nebulization in low-density polyethylene unit-dose vials. Each vial contains formoterol fumarate dihydrate, USP equivalent to 20 mcg/2 mL of formoterol fumarate.



Contraindications


All LABA, including Perforomist, are contraindicated in patients with asthma without use of a long-term asthma control medication. [see WARNINGS and PRECAUTIONS (5.1)].



Warnings and Precautions



Asthma-Related Deaths


[See BOXED WARNING]


Data from a large placebo-controlled study in asthma patients showed that long-acting beta2-adrenergic agonists may increase the risk of asthma-related death. Data are not available to determine whether the rate of death in patients with COPD is increased by long-acting beta2-adrenergic agonists.


A 28-week, placebo-controlled US study comparing the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34). The increased risk of asthma-related death is considered a class effect of the long-acting beta2-adrenergic agonists, including Perforomist Inhalation Solution. No study adequate to determine whether the rate of asthma related death is increased in patients treated with Perforomist Inhalation Solution has been conducted. The safety and efficacy of Perforomist in patients with asthma have not been established. All LABA, including Perforomist, are contraindicated in patients with asthma without use of a long-term asthma control medication. [see CONTRAINDICATIONS (4)].


Clinical studies with formoterol fumarate administered as a dry powder inhaler suggested a higher incidence of serious asthma exacerbations in patients who received formoterol than in those who received placebo. The sizes of these studies were not adequate to precisely quantify the differences in serious asthma exacerbation rates between treatment groups.



Deterioration of Disease and Acute Episodes


Perforomist Inhalation Solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. Perforomist Inhalation Solution has not been studied in patients with acutely deteriorating COPD. The use of Perforomist Inhalation Solution in this setting is inappropriate.


Perforomist Inhalation Solution should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Perforomist Inhalation Solution has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.


When beginning Perforomist Inhalation Solution, patients who have been taking inhaled, short-acting beta2-agonists on a regular basis (e.g., four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. When prescribing Perforomist Inhalation Solution, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient how it should be used. Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated. COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If Perforomist Inhalation Solution no longer controls the symptoms of bronchoconstriction, or the patient’s inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalation of short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dosage of Perforomist Inhalation Solution beyond the recommended 20 mcg twice daily dose is not appropriate in this situation.



Excessive Use and Use with Other Long-Acting Beta2-Agonists


As with other inhaled beta2-adrenergic drugs, Perforomist Inhalation Solution should not be used more often, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2-agonists, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.



Paradoxical Bronchospasm


As with other inhaled beta2-agonists, Perforomist Inhalation Solution can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, Perforomist Inhalation Solution should be discontinued immediately and alternative therapy instituted.



Cardiovascular Effects


Perforomist Inhalation Solution, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic and/or diastolic blood pressure, and/or symptoms. If such effects occur, Perforomist Inhalation Solution may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, Perforomist Inhalation Solution, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.



Coexisting Conditions


Perforomist Inhalation Solution, like other sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to sympathomimetic amines. Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.



Hypokalemia and Hyperglycemia


Beta-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects [see CLINICAL PHARMACOLOGY (12.2)]. The decrease in serum potassium is usually transient, not requiring supplementation. Beta-agonist medications may produce transient hyperglycemia in some patients.


Clinically significant changes in serum potassium and blood glucose were infrequent during clinical studies with long-term administration of Perforomist Inhalation Solution at the recommended dose.



Immediate Hypersensitivity Reactions


Immediate hypersensitivity reactions may occur after administration of Perforomist Inhalation Solution, as demonstrated by cases of anaphylactic reactions, urticaria, angioedema, rash, and bronchospasm.



Adverse Reactions


Long acting beta2-adrenergic agonists such as formoterol increase the risk of asthma-related death [See BOXED WARNING and WARNINGS AND PRECAUTIONS (5.1)].



Beta2-Agonist Adverse Reaction Profile


Adverse reactions to Perforomist Inhalation Solution are expected to be similar in nature to other beta2-adrenergic receptor agonists including: angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mouth, muscle cramps, palpitations, nausea, dizziness, fatigue, malaise, insomnia, hypokalemia, hyperglycemia, and metabolic acidosis.



Clinical Trials Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.


Adults with COPD

The data described below reflect exposure to Perforomist Inhalation Solution 20 mcg twice daily by oral inhalation in 586 patients, including 232 exposed for 6 months and 155 exposed for at least 1 year. Perforomist Inhalation Solution was studied in a 12-week, placebo- and active-controlled trial (123 subjects treated with Perforomist Inhalation Solution) and a 52-week, active-controlled trial (463 subjects treated with Perforomist Inhalation Solution). Patients were mostly Caucasians (88%) between 40-90 years old (mean, 64 years old) and had COPD, with a mean FEV1 of 1.33 L. Patients with significant concurrent cardiac and other medical diseases were excluded from the trials.


Table 1 shows adverse reactions from the 12-week, double-blind, placebo-controlled trial where the frequency was greater than or equal to 2% in the Perforomist Inhalation Solution group and where the rate in the Perforomist Inhalation Solution group exceeded the rate in the placebo group. In this trial, the frequency of patients experiencing cardiovascular adverse events was 4.1% for Perforomist Inhalation Solution and 4.4% for placebo. There were no frequently occurring specific cardiovascular adverse events for Perforomist Inhalation Solution (frequency greater than or equal to 1% and greater than placebo). The rate of COPD exacerbations was 4.1% for Perforomist Inhalation Solution and 7.9% for placebo.





















































TABLE 1
Number of patients with adverse reactions in the 12-week multiple-dose controlled clinical trial
Adverse ReactionPerforomist

Inhalation

Solution

20 mcg
Placebo
n(%)n(%)
Total Patients123(100)114(100)
Diarrhea6(4.9)4(3.5)
Nausea6(4.9)3(2.6)
Nasopharyngitis4(3.3)2(1.8)
Dry Mouth4(3.3)2(1.8)
Vomiting3(2.4)2(1.8)
Dizziness3(2.4)1(0.9)
Insomnia3(2.4)00

Patients treated with Perforomist Inhalation Solution 20 mcg twice daily in the 52-week open-label trial did not experience an increase in specific clinically significant adverse events above the number expected based on the medical condition and age of the patients.



Postmarketing Experience


The following adverse reactions have been reported during post-approval use of Perforomist Inhalation Solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.


Anaphylactic reactions, urticaria, angioedema (presenting as face, lip, tongue, eye, pharyngeal, or mouth edema), rash, and bronchospasm



Drug Interactions



Adrenergic Drugs


If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of formoterol may be potentiated [see WARNINGS AND PRECAUTIONS (5.3, 5.5, 5.6, 5.7)].



Xanthine Derivatives, Steroids, or Diuretics


Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists [see WARNINGS AND PRECAUTIONS (5.7)].



Non-potassium Sparing Diuretics


The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.



MAO Inhibitors, Tricyclic Antidepressants, QTc Prolonging Drugs


Formoterol, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.



Beta-blockers


Beta-adrenergic receptor antagonists (beta-blockers) and formoterol may inhibit the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.



USE IN SPECIFIC POPULATIONS



Pregnancy


Teratogenic Effects: Pregnancy Category C

Formoterol fumarate administered throughout organogenesis did not cause malformations in rats or rabbits following oral administration. However, formoterol fumarate was found to be teratogenic in rats and rabbits in other testing laboratories. When given to rats throughout organogenesis, oral doses of 0.2 mg/kg (approximately 40 times the maximum recommended daily inhalation dose in humans on a mg/m2 basis) and above delayed ossification of the fetus, and doses of 6 mg/kg (approximately 1200 times the maximum recommended daily inhalation dose in humans on a mg/m2 basis) and above decreased fetal weight. Formoterol fumarate has been shown to cause stillbirth and neonatal mortality at oral doses of 6 mg/kg and above in rats receiving the drug during the late stage of pregnancy. These effects, however, were not produced at a dose of 0.2 mg/kg. Because there are no adequate and well-controlled studies in pregnant women, Perforomist Inhalation Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


Women should be advised to contact their physician if they become pregnant while taking Perforomist Inhalation Solution.



Labor and Delivery


There are no adequate and well-controlled human studies that have investigated the effects of Perforomist Inhalation Solution during labor and delivery.


Because beta-agonists may potentially interfere with uterine contractility, Perforomist Inhalation Solution should be used during labor only if the potential benefit justifies the potential risk.



Nursing Mothers


In reproductive studies in rats, formoterol was excreted in the milk. It is not known whether formoterol is excreted in human milk, but because many drugs are excreted in human milk, caution should be exercised if Perforomist Inhalation Solution is administered to nursing women. There are no well-controlled human studies of the use of Perforomist Inhalation Solution in nursing mothers.


Women should be advised to contact their physician if they are nursing while taking Perforomist Inhalation Solution.



Pediatric Use


Perforomist Inhalation Solution is not indicated for use in children. The safety and effectiveness of  Perforomist Inhalation Solution in pediatric patients have not been established. The pharmacokinetics of formoterol fumarate has not been studied in pediatric patients.



Geriatric Use


Of the 586 subjects who received Perforomist Inhalation Solution in clinical studies, 284 were 65 years and over, while 89 were 75 years and over. Of the 123 subjects who received Perforomist Inhalation Solution in the 12-week safety and efficacy trial, 48 (39%) were 65 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.


The pharmacokinetics of Perforomist Inhalation Solution has not been studied in elderly subjects.



Overdosage


The expected signs and symptoms with overdosage of Perforomist Inhalation Solution are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms listed under ADVERSE REACTIONS. Signs and symptoms may include angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, and metabolic acidosis. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of Perforomist Inhalation Solution.


Treatment of overdosage consists of discontinuation of Perforomist Inhalation Solution together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Perforomist Inhalation Solution. Cardiac monitoring is recommended in cases of overdosage.


The minimum lethal inhalation dose of formoterol fumarate in rats is 156 mg/kg (approximately 32,000 times the maximum recommended daily inhalation dose in humans on a mg/m2 basis). The median lethal oral doses in Chinese hamsters, rats, and mice provide even higher multiples of the maximum recommended daily inhalation dose in humans.


  For additional information about overdose treatment, call a poison control center (1-800-222-1222).



Perforomist Description


Perforomist (formoterol fumarate) Inhalation Solution is supplied as 2 mL of formoterol fumarate inhalation solution packaged in a 2.5 mL single-use low-density polyethylene vial and overwrapped in a foil pouch. Each vial contains 2 mL of a clear, colorless solution composed of formoterol fumarate dihydrate, USP equivalent to 20 mcg of formoterol fumarate in an isotonic, sterile aqueous solution containing sodium chloride, pH adjusted to 5.0 with citric acid and sodium citrate.


The active component of  Perforomist Inhalation Solution is formoterol fumarate dihydrate, USP, a racemate. Formoterol fumarate dihydrate is a beta2-adrenergic bronchodilator. Its chemical name is (±) - 2 - hydroxy - 5 - [(1RS) - 1 - hydroxy - 2 - [[(1RS) - 2 - (4 - methoxyphenyl) - 1 - methylethyl] - amino]ethyl]formanilide fumarate dihydrate; its structural formula is:



Formoterol fumarate dihydrate, USP has a molecular weight of 840.92 and its empirical formula is (C19H24N2O4)2•C4H4O4•2H2O. Formoterol fumarate dihydrate, USP is a white to yellowish crystalline powder, which is freely soluble in glacial acetic acid, soluble in methanol, sparingly soluble in ethanol and isopropanol, slightly soluble in water, and practically insoluble in acetone, ethyl acetate, and diethyl ether.


Perforomist Inhalation Solution does not require dilution prior to administration by nebulization. Like all other nebulized treatments, the amount delivered to the lungs will depend on patient factors and the nebulization system used and its performance.


Using the PARI-LC Plus® nebulizer (with a facemask or mouthpiece) connected to a PRONEB® Ultra compressor under in vitro conditions, the mean delivered dose from the mouthpiece was approximately 7.3 mcg (37% of label claim). The mean nebulizer flow rate was 4 LPM and the nebulization time was 9 minutes. Perforomist Inhalation Solution should be administered from a standard jet nebulizer at adequate flow rates via a facemask or mouthpiece.



Perforomist - Clinical Pharmacology



Mechanism of Action


Formoterol fumarate is a long-acting, beta2-adrenergic receptor agonist (beta2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta2-receptors than at beta1-receptors. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects.


The pharmacologic effects of beta2-adrenoceptor agonist drugs, including formoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.


In vitro tests show that formoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Formoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans with COPD is unknown.



Pharmacodynamics


Systemic Safety and Pharmacokinetic / Pharmacodynamic Relationships

The major adverse effects of inhaled beta2-agonists occur as a result of excessive activation of the systemic beta-adrenergic receptors. The most common adverse effects in adults include skeletal muscle tremor and cramps, insomnia, tachycardia, decreases in plasma potassium, and increases in plasma glucose.


Changes in serum potassium and serum glucose were evaluated in 12 COPD patients following inhalation of single doses of Perforomist Inhalation Solution containing 10, 20 and 244 mcg of formoterol fumarate (calculated on an anhydrous basis) in a crossover study. At 1 hour after treatment with formoterol fumarate inhalation solution, mean (± standard deviation) serum glucose rose 26 ± 30, 29 ± 28, and 38 ± 44 mg/dL, respectively, and was not significantly different from baseline or trough level at 24 hours post-dose. At 1 hour after dosing with formoterol fumarate inhalation solution 244 mcg, serum potassium fell by 0.68 ± 0.4 mEq/L, and was not different from baseline or trough level at 24 hours post-dose.


Linear pharmacokinetic/pharmacodynamic (PK/PD) relationships between urinary formoterol excretion and decreases in serum potassium, increases in plasma glucose, and increases in heart rate were generally observed with another inhalation formulation of formoterol fumarate and hence would be expected with Perforomist Inhalation Solution also. Following single dose administration of 10-fold the recommended clinical dose of the other formoterol fumarate inhalation formulation having comparable exposure to single dose of 244 mcg of Perforomist Inhalation Solution (approximately 12-fold the recommended clinical dose) in healthy subjects, the formoterol plasma concentration was found to be highly correlated with the reduction in plasma potassium concentration. Data from this study showed that maximum reductions from baseline in plasma potassium ranged from 0.55 to 1.52 mmol/L with a median maximum reduction of 1.01 mmol/L. Generally, the maximum effect on plasma potassium was noted 1 to 3 hours after peak formoterol plasma concentrations were achieved.


Electrophysiology

In the dose-ranging study of Perforomist Inhalation Solution, ECG-determined heart rate increased by a mean of 6 ±3 beats per minute at 6 hours after a single dose of 244 mcg, but was back to predose level at 16-24 hours.


The effect of Perforomist Inhalation Solution on heart rate and cardiac rhythm was studied in a 12-week clinical trial comparing Perforomist Inhalation Solution to placebo and an active control treatment. COPD patients, including 105 patients exposed to Perforomist Inhalation Solution, underwent continuous electrocardiographic (Holter) monitoring during two 24-hour periods (study baseline and after 8-12 weeks of treatment). ECGs were performed pre-dose and at 2 to 3 hours post-dose at study baseline (prior to dosing) and after 4, 8 and 12 weeks of treatment. Bazett’s and Fridericia’s methods were used to correct the QT interval for heart rate (QTcB and QTcF, respectively). The mean increase from baseline in QTcB interval over the 12-week treatment period was ≤ 4.8 msec for Perforomist Inhalation Solution and ≤ 4.6 msec for placebo. The percent of patients who experienced a maximum change in QTc greater than 60 msec at any time during the 12-week treatment period was 0% and 1.8% for Perforomist Inhalation Solution and placebo, respectively, based on Bazett’s correction, and 1.6% and 0.9%, respectively, based on Fridericia’s correction. Prolonged QT was reported as an adverse event in 1 (0.8%) patient treated with Perforomist Inhalation Solution and 2 (1.8%) placebo patients. No occurrences of atrial fibrillation or ventricular tachycardia were observed during 24-hour Holter monitoring or reported as adverse events in patients treated with Perforomist Inhalation Solution after the start of dosing. No increase in supraventricular tachycardia over placebo-treated subjects was observed. The mean increase in maximum heart rate from baseline to 8-12 weeks after the start of dosing was 0.6 beats per minute (bpm) for patients treated with Perforomist Inhalation Solution twice daily compared to 1.2 bpm for placebo patients. There were no clinically meaningful differences from placebo in acute or chronic effects on heart rate, including QTcB and QTcF, or cardiac rhythm resulting from treatment with Perforomist Inhalation Solution.


At an exposure from formoterol fumarate dry powder formulation comparable to approximately 12-fold the recommended dose of Perforomist Inhalation Solution, a mean maximum increase of pulse rate of 26 bpm was observed 6 hours post dose in healthy subjects. This study showed that the maximum increase of mean corrected QT interval (QTc) was 25 msec when calculated using Bazett's correction and was 8 msec when calculated using Fridericia's correction. The QTc returned to baseline within 12 to 24 hours post-dose. Formoterol plasma concentrations were weakly correlated with pulse rate and increase of QTc duration. The effects on pulse rate and QTc interval are known pharmacological effects of this class of study drug and were not unexpected at this supratherapeutic formoterol fumarate inhalation dose.


Tachyphylaxis / Tolerance

Tolerance to the effects of inhaled beta-agonists can occur with regularly-scheduled, chronic use. In a placebo-controlled clinical trial in 351 adult patients with COPD, the bronchodilating effect of Perforomist Inhalation Solution was determined by the FEV1 area under the curve over 12 hours following dosing on Day 1 and after 12 weeks of treatment. The effect of Perforomist Inhalation Solution did not decrease after 12 weeks of twice-daily treatment (Figures 1 and 2).



Pharmacokinetics


Information on the pharmacokinetics of formoterol (dry powder and/or inhalation solution) in plasma and/or urine is available in healthy subjects as well as patients with chronic obstructive pulmonary disease after oral inhalation of doses at and above the therapeutic dose.


Urinary excretion of unchanged formoterol was used as an indirect measure of systemic exposure. Plasma drug disposition data parallel urinary excretion, and the elimination half-lives calculated for urine and plasma are similar.


Absorption

Pharmacokinetic properties of formoterol fumarate were evaluated in 12 COPD patients following inhalation of single doses of Perforomist Inhalation Solution containing 10, 20 and 244 mcg of formoterol fumarate (calculated on an anhydrous basis) and 12 mcg formoterol fumarate dry powder, through 36 hours after single-dose administration. Formoterol fumarate concentrations in plasma following the 10 and 20 mcg doses of Perforomist Inhalation Solution and the 12 mcg dose of formoterol fumarate dry powder were undetectable or only detected sporadically at very low concentrations. Following a single 244 mcg dose of Perforomist Inhalation Solution (approximately 12 times the recommended clinical dose), formoterol fumarate concentrations were readily measurable in plasma, exhibiting rapid absorption into plasma, and reaching a maximum drug concentration of 72 pg/mL within approximately 12 minutes of dosing.


The mean amount of formoterol excreted unchanged in 24 hour urine following single oral inhalation doses of 10, 20, and 244 mcg Perforomist Inhalation Solution were found to be 109.7 ng, 349.6 ng, and 3317.5 ng, respectively. These findings indicate a near dose proportional increase in systemic exposure within the dose range tested.


When 12 mcg of a dry powder formulation of formoterol fumarate was given twice daily to COPD patients by oral inhalation for 12 weeks, the accumulation index, based on the urinary excretion of unchanged formoterol was 1.19 to 1.38. This suggests some accumulation of formoterol in plasma with multiple dosing. Although multiple-dose pharmacokinetic data is unavailable from Perforomist Inhalation Solution, assumption of linear pharmacokinetics allows a reasonable prediction of minimal accumulation based on single-dose pharmacokinetics. As with many drug products for oral inhalation, it is likely that the majority of the inhaled formoterol fumarate delivered is swallowed and then absorbed from the gastrointestinal tract.


Distribution

The binding of formoterol to human plasma proteins in vitro was 61% to 64% at concentrations from 0.1 to 100 ng/mL. Binding to human serum albumin in vitro was 31% to 38% over a range of 5 to 500 ng/mL. The concentrations of formoterol used to assess the plasma protein binding were higher than those achieved in plasma following inhalation of a single 244 mcg dose of Perforomist Inhalation Solution.


Metabolism

Formoterol is metabolized primarily by direct glucuronidation at either the phenolic or aliphatic hydroxyl group and O-demethylation followed by glucuronide conjugation at either phenolic hydroxyl groups. Minor pathways involve sulfate conjugation of formoterol and deformylation followed by sulfate conjugation. The most prominent pathway involves direct conjugation at the phenolic hydroxyl group. The second major pathway involves O-demethylation followed by conjugation at the phenolic 2'-hydroxyl group. In vitro studies showed that multiple drug-metabolizing enzymes catalyze glucuronidation (UGT1A1, 1A8, 1A9, 2B7 and 2B15 were the most predominant enzymes) and O-demethylation (CYP2D6, CYP2C19, CYP2C9 and CYP2A6) of formoterol. Formoterol did not inhibit CYP450 enzymes at therapeutically relevant concentrations. Some patients may be deficient in CYP2D6 or 2C19 or both. Whether a deficiency in one or both of these isozymes results in elevated systemic exposure to formoterol or systemic adverse effects has not been adequately explored.


Excretion

Following administration of single 10, 20, and 244 mcg Perforomist Inhalation Solution doses (calculated on an anhydrous basis) delivered via nebulizer in 12 COPD patients, on average, about 1.1% to 1.7% of the dose was excreted in the urine as unchanged formoterol as compared to about 3.4% excreted unchanged following inhalation administration of 12 mcg of formoterol fumarate dry powder. Renal clearance of formoterol following inhalation administration of Perforomist Inhalation Solution in these subjects was about 157 mL/min. Based on plasma concentrations measured following the 244 mcg dose, the mean terminal elimination half-life was determined to be 7 hours.


Gender

As reported for another formoterol fumarate inhalation formulation, upon correction for body weight, pharmacokinetics of formoterol fumarate  did not differ significantly between males and females.


Geriatric, Pediatric, Hepatic/Renal Impairment

The pharmacokinetics of formoterol fumarate has not been studied in elderly and pediatric patient populations. The pharmacokinetics of formoterol fumarate has not been studied in subjects with hepatic or renal impairment.



Nonclinical Toxicology



Carcinogenesis, Mutagenesis, Impairment of Fertility


The carcinogenic potential of formoterol fumarate has been evaluated in 2-year drinking water and dietary studies in both rats and mice. In rats, the incidence of ovarian leiomyomas was increased at doses of 15 mg/kg and above in the drinking water study and at 20 mg/kg in the dietary study (AUC exposure approximately 2300 times human exposure at the maximum recommended daily inhalation dose), but not at dietary doses up to 5 mg/kg (AUC exposure approximately 570 times human exposure at the maximum recommended daily inhalation dose). In the dietary study, the incidence of benign ovarian theca-cell tumors was increased at doses of 0.5 mg/kg (AUC exposure was approximately 57 times human exposure at the maximum recommended daily inhalation dose) and above. This finding was not observed in the drinking water study, nor was it seen in mice (see below).


In mice, the incidence of adrenal subcapsular adenomas and carcinomas was increased in males at doses of 69 mg/kg (AUC exposure approximately 1000 times human exposure at the maximum recommended daily inhalation dose) and above in the drinking water study, but not at doses up to 50 mg/kg (AUC exposure approximately 750 times human exposure at the maximum recommended daily inhalation dose) in the dietary study. The incidence of hepatocarcinomas was increased in the dietary study at doses of 20 and 50 mg/kg in females (AUC exposures approximately 300 and 750 times human exposure at the maximum recommended daily inhalation dose, respectively) and 50 mg/kg in males, but not at doses up to 5 mg/kg (AUC exposure approximately 75 times human exposure at the maximum recommended daily inhalation dose). Also in the dietary study, the incidence of uterine leiomyomas and leiomyosarcomas was increased at doses of 2 mg/kg (AUC exposure was approximately 30 times human exposure at the maximum recommended daily inhalation dose) and above. Increases in leiomyomas of the rodent female genital tract have been similarly demonstrated with other beta-agonist drugs.


Formoterol fumarate was not mutagenic or clastogenic in the following tests: mutagenicity tests in bacterial and mammalian cells, chromosomal analyses in mammalian cells, unscheduled DNA synthesis repair tests in rat hepatocytes and human fibroblasts, transformation assay in mammalian fibroblasts and micronucleus tests in mice and rats.


Reproduction studies in rats revealed no impairment of fertility at oral doses up to 3 mg/kg (approximately 600 times the maximum recommended daily inhalation powder dose in humans on a mg/m2 basis).



Animal Pharmacology


Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines are administered concurrently. The clinical significance of these findings is unknown. [See DRUG INTERACTIONS, Xanthine Derivatives, Steroids, or Diuretics (7.2)]



Clinical Studies



Adult COPD Trial


Perforomist (formoterol fumarate) Inhalation Solution was evaluated in a 12-week, double-blind, placebo- and active-controlled, randomized, parallel-group, multicenter trial conducted in the United States. Of a total enrollment of 351 adults (age range: 40 to 86 years; mean age: 63 years) with COPD who had a mean pre-bronchodilator FEV1 of 1.34 liters (44% of predicted), 237 patients were randomized to Perforomist Inhalation Solution 20 mcg or placebo, administered twice daily via a PARI-LC Plus® nebulizer with a PRONEB® Ultra compressor. The diagnosis of COPD was based upon a prior clinical diagnosis of COPD, a smoking history (at least 10 pack-years), age (at least 40 years), and spirometry results (pre-bronchodilator baseline FEV1 at least 30% and less than 70% of the predicted value, and the FEV1/FVC less than 70%). About 58% of patients had bronchodilator reversibility, defined as a 10% or greater increase in FEV1 after inhalation of 2 actuations (180 mcg) of albuterol from a metered dose inhaler. About 86% (106) of patients treated with Perforomist Inhalation Solution and 74% (84) of placebo patients completed the trial.


Perforomist Inhalation Solution 20 mcg twice daily resulted in significantly greater post-dose bronchodilation (as measured by serial FEV1 for 12 hours post-dose; the primary efficacy analysis) compared to placebo when evaluated at endpoint (week 12 for completers and last observation for dropouts). Similar results were seen on Day 1 and at subsequent timepoints during the trial.


Mean FEV1 measurements at Day 1 (Figure 1) and at endpoint (Figure 2) are shown below.


Figure 1 Mean1 FEV1 at Day 1



Figure 2 Mean1 FEV1 at Endpoint after 12 Weeks of Treatment



Patients treated with Perforomist Inhalation Solution used less rescue albuterol during the trial compared to patients treated with placebo.


Examination of age (≥ 65 or younger) and gender subgroups did not identify differences in response to Perforomist Inhalation Solution. There were too few non-Caucasian subjects to assess differences in populations defined by race adequately.


In the 12 week study, 78% of subjects achieved a 15% increase from baseline FEV1 following the first dose of Perforomist Inhalation Solution 20 mcg. In these subject

potassium citrate


poe-TAS-ee-um SIT-rate


Commonly used brand name(s)

In the U.S.


  • Urocit-K 10

  • Urocit-K 15

  • Urocit-K 5

Available Dosage Forms:


  • Patch, Extended Release

  • Tablet, Extended Release

  • Tablet

  • Solution

Therapeutic Class: Urinary Alkalinizer


Uses For potassium citrate


Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. It is also used to prevent kidney stones that may occur with gout.


Potassium citrate is a urinary alkalinizer. It works by making the urine more alkaline (less acid).


potassium citrate is available only with your doctor's prescription.


Before Using potassium citrate


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For potassium citrate, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to potassium citrate or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of potassium citrate in the pediatric population. Safety and efficacy have not been established.


Geriatric


No information is available on the relationship of age to the effects of potassium citrate in geriatric patients.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of potassium citrate. Make sure you tell your doctor if you have any other medical problems, especially:


  • Acidosis (high acid in the blood) or

  • Electrolyte imbalance (high or low sodium, chloride, or carbon dioxide in the blood) or

  • Heart disease or

  • Kidney disease—Use with caution. May make these conditions worse.

  • Adrenal problems or

  • Dehydration or

  • Diabetes mellitus, uncontrolled or

  • Hyperkalemia (high potassium in the blood) or

  • Kidney failure or

  • Infection (e.g., urinary tract infection) or

  • Peptic ulcer or

  • Stomach problems (e.g., intestinal blockage, digestion problems) or

  • Tissue injury—Should not be used in patients with these conditions.

Proper Use of potassium citrate


Take potassium citrate exactly as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. To do so may increase the chance of side effects.


In addition to the use of potassium citrate, treatment for your kidney stones may include changes in the types of foods you eat, especially foods high in sodium (salt). Your doctor will tell you which of these are most important for you. You should check with your doctor before changing your diet.


It is best to take potassium citrate with a meal or bedtime snack, or within 30 minutes after meals.


Swallow the extended-release tablet whole. Do not break, crush, chew, or suck it. Doing so, may cause irritation in the mouth or throat.


Tell your doctor if you have trouble swallowing the tablets, or if the tablet seems to stick or gets stuck in your throat.


While taking the extended-release tablet, part of it may pass into your stools. This is normal and is nothing to worry about.


Drink extra fluids so you will pass more urine while you are using potassium citrate. This will keep your kidneys working well and help prevent kidney problems.


Dosing


The dose of potassium citrate will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of potassium citrate. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage form (extended-release tablets):
    • For treatment and prevention of kidney stones:
      • Adults—At first, 15 to 30 milliequivalents (mEq) two times a day, or 10 to 20 mEq three times a day. Your doctor may increase your dose as needed. However, the dose is usually not more than 100 mEq per day.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of potassium citrate, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using potassium citrate


It is very important that your doctor check your progress at regular visits to make sure that potassium citrate is working properly. Blood and urine tests may be needed to check for unwanted effects.


You should not take potassium citrate if you are also using atropine, benztropine (Cogentin®), glycopyrrolate (Robinul®), or a diuretic or "water pill" (such as amiloride, spironolactone, triamterene, Aldactone®, Dyrenium®, or Midamor®). Using these medicines together may cause serious problems.


Hyperkalemia (high potassium in the blood) may occur while you are using potassium citrate. Stop using potassium citrate and check with your doctor right away if you have the following symptoms: abdominal or stomach pain; confusion; difficulty with breathing; irregular heartbeat; nausea or vomiting; nervousness; numbness or tingling in the hands, feet, or lips; shortness of breath; or weakness or heaviness of the legs.


Stop using potassium citrate and check with your doctor right away if you have bloody or black, tarry stools; constipation; severe stomach pain; or vomiting of blood or material that looks like coffee grounds. These may be symptoms of a serious stomach problem.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.


potassium citrate Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Incidence not known
  • Abdominal or stomach discomfort

  • diarrhea

  • nausea

  • vomiting

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptoms of overdose
  • Abdominal or stomach pain

  • confusion

  • difficult breathing

  • irregular heartbeat

  • nervousness

  • numbness or tingling in the hands, feet, or lips

  • shortness of breath

  • weakness or heaviness of the legs

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: potassium citrate side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More potassium citrate resources


  • Potassium citrate Side Effects (in more detail)
  • Potassium citrate Use in Pregnancy & Breastfeeding
  • Drug Images
  • Potassium citrate Drug Interactions
  • Potassium citrate Support Group
  • 0 Reviews for Potassium citrate - Add your own review/rating


  • potassium citrate Concise Consumer Information (Cerner Multum)

  • Potassium Citrate MedFacts Consumer Leaflet (Wolters Kluwer)

  • Potassium Citrate Prescribing Information (FDA)

  • Urocit-K Prescribing Information (FDA)



Compare potassium citrate with other medications


  • Nephrolithiasis
  • Renal Tubular Acidosis